Allogene Therapeutics, Inc. (ALLO) Guidance & Earnings Results
On 2025-11-06 Allogene Therapeutics, Inc. reaffirmed guidance: "Cash runway into 2H 2027; 2025 cash burn…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ALLOAllogene Therapeutics, Inc.Follow ALLO — free
—
Price chart with a free account
- Market cap
- 431.9M
- P/E TTM
- —
- Dividend yield
- 0.0%
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 6 Nov 25 | Reaffirmed | Cash runway into 2H 2027; 2025 cash burn ~$150M · full year |
| 13 Aug 25 | Reaffirmed | 2025 cash burn ~$150M; GAAP OpEx ~$230M · full year |
Allogene Therapeutics, Inc. — questions
- What guidance did Allogene Therapeutics, Inc. give?
- On 2025-11-06: "Cash runway into 2H 2027; 2025 cash burn ~$150M"
- When does Allogene Therapeutics, Inc. report earnings?
- Allogene Therapeutics, Inc.'s next earnings report is expected on 2026-10-29.
Every figure on this page comes from Allogene Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.